The Development of siRNA-Based Therapies for Cancer. Table II
http://pharmaceuticalintelligence.com
Author: Ziv Raviv PhD
Table : Current clinical trials of siRNA therapies for cancer
Drug
Sponsor
Target gene
Cancer type
Status
Not indicated
Alnylam Pharmaceuticals
CLDN3
Ovarian cancer
preclinical
BP-100-2.01
Bio-Path Holdings
PTK2 (FAK)
Solid tumors
preclinical
BC-822
BioCancell Therapeutics
H19
Solid tumors
preclinical
CALAA-02
Calando Pharmaceuticals
(Arrowhead Research
Corporation)
EPAS1 (HIF2alpha)
Solid tumors
Preclinical
ICS-283
Silence Therapeutics
VEGF; FLT1;
KDR
Solid tumors
Preclinical
Atu134
Silence Therapeutics
PKAM1
(CD31)
Solid tumors
Preclinical
Atu195
Silence Therapeutics
N/A
Liver cancer
Preclinical
Sirna-027
Sirna Therapeutics
FLT1 (VEGFr1)
Breast cancer
Preclinical
ALN-VSP
Alnylam Pharmaceuticals
KSP & VEGF
Liver cancer: primary
or metastatic,
refractory or
progressive
Phase I
Atu027
Silence Therapeutics
PKN3
Solid tumors,
advanced, recurrent
or metastatic
Phase I
CALAA-01
Calando Pharmaceuticals
(Arrowhead Research
Corporation)
RRM2
Solid tumors
Phase I
siG12D
LODER
Silenseed Ltd
KRAS G12D
Pancreatic cancer
Phase I
siRNA-EphA2DOPC
M.D. Anderson Cancer
Center
EphA2
Solid tumors:
advanced, recurrent
cancer
Phase I
TKM080301
Tekmira
Pharmaceuticals;
National Cancer Institute
(NCI)
PLK1
Primary or secondary
Liver cancer
Phase I
The Development of siRNA-Based Therapies for Cancer. Table II
http://pharmaceuticalintelligence.com
Author: Ziv Raviv PhD
Combination with Chemotherapy:
Atu027 +
Gemcitabine
Silence Therapeutics
PKN3
Pancreatic cancer
Phase I/
Phase II
Table resources: nmOK drug database, clinicaltrials.gov, and World Health Organization (WHO)